Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with palbociclib, and the OPERA-01 Phase 3 clinical trial in progress will be presented on Dec. 7, 2023
Olema will host an investor conference call at 8:00 a.m. ET on Dec. 8, 2023
SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that it will be presenting new Phase 1b/2 clinical data of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib, a Poster Spotlight Session on Phase 2 clinical data of palazestrant in combination with palbociclib, and a trial-in-progress poster for the OPERA-01 monotherapy Phase 3 pivotal trial at the upcoming San Antonio Breast Cancer Symposium (SABCS) being held December 5-9, 2023, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
Details of the SABCS 2023 poster presentations are:
Title: | A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, advanced and/or metastatic breast cancer. |
Poster ID: | PO4-04-12 |